<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11556827</article-id><article-id pub-id-type="pmc">2375071</article-id><article-id pub-id-type="pii">6692001</article-id><article-id pub-id-type="doi">10.1054/bjoc.2001.2001</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kalbakis</surname><given-names>K</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kouroussis</surname><given-names>Ch</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kakolyris</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mavroudis</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Souglakos</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Agelaki</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Vamvakas</surname><given-names>L</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Christodoulakis</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Stylianou</surname><given-names>K</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Georgoulias</surname><given-names>V</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Medical Oncology, School of Medicine, University General Hospital of Heraklion,, P.O. Box 1352, Heraklion, Crete, 71110, Greece</aff><aff id="aff2"><label>2</label>Department Surgery Oncology, School of Medicine, University General Hospital of Heraklion, P.O. Box 1352, Heraklion, Crete, 71110, Greece</aff><pub-date pub-type="ppub"><month>09</month><year>2001</year></pub-date><volume>85</volume><issue>6</issue><fpage>798</fpage><lpage>802</lpage><history><date date-type="received"><day>11</day><month>01</month><year>2001</year></date><date date-type="rev-recd"><day>02</day><month>05</month><year>2001</year></date><date date-type="accepted"><day>04</day><month>07</month><year>2001</year></date></history><copyright-statement>Copyright 2001, Cancer Research Campaign</copyright-statement><copyright-year>2001</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>The purpose of this study was to evaluate the activity and tolerance of high-dose leucovorin (LV) and infusional 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) as salvage chemotherapy in patients with metastatic breast cancer (MBC) pretreated with anthracyclines and taxanes. 41 patients (median age 59 years) with MBC refractory or resistant to anthracyclines and taxanes were enrolled. The patients' performance status (WHO) was 0 in 10 patients (24&#x00025;), 1 in 22 (54&#x00025;), and 2 in 9 (22&#x00025;). 30 (73&#x00025;) patients had received 2 or more prior chemotherapy regimens. Cyclophosphamide (600&#x02008;mg&#x02008;m<sup>&#x02212;2</sup>) was given i.v. bolus on day 1 and LV (500&#x02008;mg&#x02008;m<sup>&#x02212;2</sup> d<sup>&#x02212;1</sup>) as a 2-h infusion followed by 5-FU (1.5&#x02008;g&#x02008;m<sup>&#x02212;2</sup> d<sup>&#x02212;1</sup>) over a 22&#x02008;h c.i. for 2 consecutive days. Cyclophosphamide was administered every 28 days while 5-FU/LV every 14 days. In an intention-to-treat analysis, complete response (CR) was achieved in 2 (4.9&#x00025;) patients and partial response (PR) in 9 (22&#x00025;) (overall response rate 26.9&#x00025;; 95&#x00025; CI: 13.27&#x02013;40.39&#x00025;). Stable disease (SD) and progressive disease (PD) were observed in 9 (22&#x00025;) and 21 (51&#x00025;) patients, respectively. The overall response rate was 6&#x00025; and 40&#x00025; in patients with primary and secondary resistance to anthracyclines/taxanes, respectively (<italic>P</italic> = 0.047). The median duration of response and the median time to disease progression was 8 and 9.5 months, respectively. The median overall survival was 13 months and the probability for 1-year survival 51&#x00025;. Grade 3/4 neutropenia occurred in 9 (22&#x00025;) patients and 4 (9&#x00025;) patients developed grade 3/4 thrombocytopenia. Non-haematological toxicity was mild. There were no cases of febrile neutropenia, toxic deaths or treatment-related hospital admissions due to toxicity. The combination of high-dose 5-FU/LV with conventional doses of cyclophosphamide is a well tolerated and effective salvage regimen in patients with MBC heavily pretreated with both anthracyclines and taxanes. &#x000a9; 2001 Cancer Research Campaign<ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.bjcancer.com">http://www.bjcancer.com</ext-link>http://www.bjcancer.com</p></abstract><kwd-group><kwd>breast cancer</kwd><kwd>salvage chemotherapy</kwd><kwd>cyclophosphamide</kwd><kwd>5-fluorouracil</kwd><kwd>leucovorin</kwd><kwd>anthracycline/taxane resistance</kwd></kwd-group></article-meta></front></article>


